Phase IV, Open-Label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART [highly active antiretroviral therapy] in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on Their HAART Regimen
Latest Information Update: 30 Jul 2009
At a glance
- Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 01 Jun 2009 Results published in the Journal of Acquired Immune Deficiency Syndrome.
- 09 Nov 2008 Results were presented at the 9th International Congress on Drug Therapy in HIV Infection.
- 09 Nov 2008 Results were presented at the 9th International Congress on Drug Therapy in HIV Infection.